Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes. Dudani, S., Gan, C., Wells, C., Bakouny, Z., Dizman, N., Pal, S. K., Wood, L., Kollmannsberger, C. K., Szabados, B., Powles, T., Beuselinck, B., Donskov, F., Hansen, A., Bjarnason, G. A., Canil, C. M., Srinivas, S., Agarwal, N., Liow, E., Choueiri, T. K., Heng, D. AMER SOC CLINICAL ONCOLOGY. 2020
View details for Web of Science ID 000560368302318